News - Biogen Idec


Current filters:

Biogen Idec

Popular Filters

76 to 100 of 103 results

Biogen Idec 1st-qtr sales up 7% but fail to match expectations


US biotech company Biogen Idec (Nasdaq: BIIB) post first-quarter 2012 sales of $1.29 billion, a rise…

Biogen IdecBiotechnologyFinancial

Positive Ph III data for Biogen Idec's oral MS drug candidate BG-12


US biotech firm Biogen Idec (Nasdaq: BIIB) says that detailed positive data from CONFIRM, the second…

Biogen IdecBiotechnologydimethyl fumarateNeurologicalResearch

Biogen Idec files oral MS candidate in USA


US biotech firm Biogen Idec (Nadaq: BIIB) has submitted its orally-active drug for relapsing-remitting…

Biogen IdecBiotechnologyNeurologicalRegulation

Biogen Idec in deal to buy Stromedix


S biotech firm Biogen Idec (Nasdaq: BIIB) has entered into a definitive agreement to acquire Stromedix,…

Biogen IdecBiotechnologyMergers & AcquisitionsStromedix

Sobi and Biogen Idec flesh out details of hemophilia programs


Stockholm-based Swedish Orphan Biovitrum (STO: SOBI) and US biotech company Biogen Idec (Nasdaq: BIIB)…

Biogen IdecBiotechnologyCardio-vascularLicensingPharmaceuticalSwedish Orphan Biovitrum

Solid 2011 financials from Biogen Idec but forecast disappoints


US biotech firm Biogen Idec (Nasdaq: BIIB) announced its full year and fourth quarter 2011 results which…

Biogen IdecBiotechnologyFinancial

FDA updates Tysabri label relating to anti-JCV


The US Food and Drug Administration on Friday approved a product label change for Tysabri (natalizumab),…

Biogen IdecBiotechnologyElanNeurologicalNorth AmericaPharmaceuticalRegulationTysabri

Biogen Idec prepares for multiple launches in coming years


US biotech firm Biogen Idec (Nasdaq: BIIB) outlined its plans for driving the continued strong commercial…

Biogen IdecBiotechnologyMarkets & MarketingResearch

Isis Pharma could earn $299 million from Biogen Idec deal


US biotech firm Biogen Idec (Nasdaq: BIIB) has entered into an exclusive, worldwide option and collaboration…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingRare diseasesResearch

Biogen Idec forms JV with Korea’s Samsung for biosimilars


US biotechnology firm Biogen Idec (Nasdaq: BIIB) has entered into an agreement with Korea’s largest…

Biogen IdecSamsung BioLogics

US court rules in GlaxoSmithKline’s favor in Arzerra patent dispute


A US District Court has entered final judgment in favor of UK pharma giant GlaxoSmithKline (LSE: GSK)…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineLegalNorth AmericaOncologyPatentsPharmaceuticalRoche

MS drugs push Biogen Idec 3rd-qtr 2011 net income 38% higher


US biotech company Biogen Idec (Nasdaq: BIIB) posted third-quarter 2011 financial results, showing that…

Biogen IdecBiotechnologyFinancial

Biogen Idec in up to $553 million deal with Portola for oral Syk inhibitor program


USA-based Biogen Idec (Nasdaq: BIIB) and Portola Pharmaceutical have entered into an exclusive, worldwide…

Anti-Arthritics/RheumaticsBiogen IdecBiotechnologyLicensingPharmaceuticalPortola PharmaceuticalsRare diseasesResearch

Early treatment with Biogen and Elan’s Tysabri reduces MS relapse rates


US biotech firm Biogen Idec (Nasdaq: BIIB) and Ireland-based Elan Corp (NYSE: ELN) have released new…

Biogen IdecBiotechnologyElanImmunologicalsNeurologicalPharmaceuticalResearchTysabri

Biogen Idec takes full control of Dompe JVs


US biotech firm Biogen Idec (Nasdaq: BIIB) says it will acquire 100% of Milan, Italy-headquartered Dompe…

Biogen IdecBiotechnologyDompeMarkets & MarketingNeurological

Biogen Idec and Abbott MS drug candidate daclizumab positive in Ph IIb


US biotech Biogen Idec (Nasdaq: BIIB) and health care giant Abbott Laboratories (NYSE: ABT ) have announced…

Abbott LaboratoriesBiogen IdecBiotechnologydaclizumabNeurologicalPharmaceuticalResearch

Biogen Idec posts 28% rise in Tysabri sales for 2nd-qtr 2011


USA-based biotechnology company Biogen Idec (Nasdaq: BIIB) announced its second quarter 2011 results,…

Biogen IdecBiotechnologyFinancial

European Commission gives conditional OK for Biogen Idec’s MS drug Fampyra


The European subsidiary of US biotech firm Biogen Idec (Nasdaq: BIIB) has received conditional approval…

Acorda TherapeuticsAmpyraBiogen IdecEuropeFampyraNeurologicalPharmaceuticalRegulation

Novel approach for multiple sclerosis treatment identified by Biogen Idec


US biotech firm Biogen Idec (Nasdaq: BIIB) has revealed results from a study that suggest that inhibiting…

Biogen IdecBiotechnologyNeurologicalPharmaceuticalResearch

EU clears anti-JC virus risk labeling for Biogen and Elan’s Tysabri


US biotech firm Biogen Idec (Nasdaq: BIIB) and Ireland-based Elan (NYSE: ELN) said yesterday that the…

Biogen IdecBiotechnologyElanEuropeNeurologicalRegulationTysabri

76 to 100 of 103 results

Back to top